Noble Life Sciences, a Maryland-based preclinical contract research organization (CRO), has partnered with PneumoDose, LLC, the developer of an inhalation aerosol technology that delivers drug product directly to the lungs of various disease models in animals. PneumoDose technology efficiently delivers aerosol products directly to the lungs of several dozen rodents or large animals simultaneously, ensuring reproducibility while reducing drug needed for testing. This innovative technology generates pharmaceutical micro-particles and nanoclustering of biological reagents for optimal delivery into the alveoli sacs within the lungs of rodents and other research animal models with increased solubility. This inhalation delivery system, coupled with the particlization, increases localized concentration and bioavailability of the treatment by bypassing both first liver pass and renal excretion.

Dr. Srujana Cherukuri, CEO of Noble Life Sciences, stated, “This technology really opens the door for our lung and respiratory research clients, offering them a superior tool for delivering biological agents to effect or replicate a pulmonary disease state. In addition, this device presents opportunities to develop new pharmaceutical drugs to test against biological or chemical insults, with the potential to revolutionize the management of COPD, asthma, pneumonia, and other respiratory diseases or disorders.”

“PneumoDose is very excited to partner with Noble Life Sciences and help them provide advanced aerosol capabilities to their clients,” said PneumoDose CEO and Co-Founder Dr. Mark Bailey. “We are looking forward to a great relationship with Noble.”

About Noble Life Sciences, Inc.
Noble Life Sciences is a woman-owned, preclinical CRO operated by scientists with expertise in pharmaceutical development. The company provides GLP and non-GLP preclinical services designed to accelerate development of drugs, vaccines, and medical devices. Noble offers services in pharmacology, disease models, early safety assessments, toxicology, GLP custom polyclonal antibodies, cell line development, and analytical testing.

About PneumoDose, LLC
PneumoDose is a veteran-owned pharmaceutical technology company founded by a team of scientists and engineers with decades of combined experience in aerosol research. The company focuses on bringing advanced aerosol capabilities to preclinical inhalational drug studies, significantly reducing the time and investment required for pharmaceutical companies to generate high-quality GLP or non-GLP data sets to support new inhalational drug or pulmonary disease model development.